How UKTI Can Help Your Business

UKTI Life Science Investment Organisation (LSIO)

UKTI has established a dedicated unit, the LSIO, to act as your interface with the UK life science sector. The LSIO is your guide to identifying research, development and delivery partners and will support you through every step of investing in and working in the UK. The UKTI LSIO team will work closely with you to understand your needs and requirements, partnering you with the right people in the UK.

For further information please contact the UKTI LSIO team at:
T: +44 (0)20 7333 5442
E: enquiries@ukti-invest.com
W: www.ukti.gov.uk/lifesciences
@UKTI_LSIO

For further information please contact the UKTI LSIO team:
T: +44 (0)20 7333 5442
E: enquiries@ukti-invest.com
W: www.ukti.gov.uk/lifesciences
@UKTI_LSIO

Withdrawn 17 May 2019
In 2012, annual revenue from regenerative medicine products surpassed the $1 billion mark. The global regenerative medicine market is predicted to grow to over $35 billion by 2019.

Europe has the second largest regenerative medicine ecosystem in the world with over 400 companies related to regenerative medicine. Nearly one in three of SMEs active in Europe's Advanced Therapy Medicinal Product (ATMP) market are based in the UK.

Revenues from European sales of stem cell products alone is expected to reach $1.5 billion by 2016.

Regenerative medicine has the potential to:
- Tackle the challenge of an ageing population
- Reduce healthcare costs by providing a cure or better management for chronic or hard to treat diseases
- Reduce the time and cost of drug development.

Critically we are now seeing the promise of regenerative medicine starting to become a reality with a number of successfully launched products. Four ATMPs have been approved in Europe and have been put in place to support R&D and business growth. Four ATMPs have now been approved in Europe (Glybera, ChondroCelect, MACI and Provenge).

Ease of Doing Business

The UK’s business environment has changed. It is now focused on catalysing innovation and commercial success. New fiscal incentives have been put in place to support R&D and business growth.

The UK offers businesses:
- Low corporation tax rate: dropping to 21% by April 2014
- Patent Box will reduce corporation tax on profits from UK patents to 10%
- R&D tax relief for both large corporations and smaller companies investing in R&D in the UK, applicable to direct research costs as well as contract research costs
- Funding for business growth (in England and the Devolved Administrations), and R&D funding.

Rich Diverse Ecosystem

1. World-class resources: funding, research, talent and facilities
- Dedicated funding channelled through leading researchers and centres of excellence
- £180 million Biomedical Catalyst funding allocated to industry
- The Technology Strategy Board (TSB) supports Regenerative Medicine thematic R&D competition grants
- Commissions in 2013 has already committed a further £50 million to a competition in this area
- Leading cell and tissue banking facilities
- Access to the talent and expertise needed to make your business a success.

2. Strong supply chain: fast and cost effective
- £500 million annual investment in health research infrastructure
- Simplified access to the NHS through National Health Service for Clinical Research Translational Medicine, National Institute for Health Research (NIHR) Biomedical Research Centres and Research Units
- Access to the talent and expertise needed to make your business a success.

3. Manufacturing capabilities: established and ready to work with you
- Established and experienced Good Manufacturing Practice (GMP) and ATMP manufacturing facilities
- Manufacturing innovation expertise
- Manufacturing support and expertise through established contract manufacturing organisations (CMOs) and the Cell Therapy Catapult.

4. Clinical research infrastructure: efficient clinical trial delivery
- £500 million annual investment in health research infrastructure
- Simplified access to the NHS through National Health Service for Clinical Research Translational Medicine, National Institute for Health Research (NIHR) Biomedical Research Centres and Research Units
- Access to the talent and expertise needed to make your business a success.

5. Commercial support through partnership with the Cell Therapy Catapult
- £500 million annual investment in health research infrastructure
- Simplified access to the NHS through National Health Service for Clinical Research Translational Medicine, National Institute for Health Research (NIHR) Biomedical Research Centres and Research Units
- Access to the talent and expertise needed to make your business a success.

6. NHS, your gateway to Europe & the global markets: reach your market with confidence
- £500 million annual investment in health research infrastructure
- Simplified access to the NHS through National Health Service for Clinical Research Translational Medicine, National Institute for Health Research (NIHR) Biomedical Research Centres and Research Units
- Access to the talent and expertise needed to make your business a success.

Market Opportunity

Join other international and UK businesses in exploiting the market and accessing expertise and opportunities that can facilitate success.

Rehnoun has been awarded a £1.5 million grant from the Technology Strategy Board (TSB), an innovation catalyst in the UK’s environment, to support the development of Glybera, the world’s first approved regenerative medicine product.

In 2012, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Athersys’ application to expand its ongoing Phase II study evaluating the administration of Multistem™ therapy to patients who have suffered an ischemic stroke. Ethics Committee review was successfully completed in August, 2013, and enrolment at multiple UK sites will commence following the completion of final preparations at participating clinical centres. The study is expected to enrol approximately 136 patients in total.

GE Healthcare invested £3 million in state of the art laboratories in Wales.

In 2012, GE Healthcare Life Sciences, a business unit of GE Healthcare, opened its new £3 million cell science laboratories in Cardiff, Wales. The state-of-the-art investment at the company’s Maynard Centre creates a world-class facility for research and technology innovation in cell science, to help advance the rapidly emerging fields of cell therapy and cell bioprocessing, and to support the development of new, more effective and safer medicines.